8-K filed Jul 27, 2026 at 16:08 ET
OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net loss of $0.01 per share, significantly beating the consensus estimate of -$0.11. The beat was driven by a $29.4M non-cash revenue recognition from shares received in the Nicoya agreement amendment and a $18.1M earnout from the Labcorp asset sale, masking ongoing weakness in core diagnostics revenue, which fell to $74.5M from $101.1M a year ago. Full-year revenue guidance was raised to $560M-$585M from the prior $530M-$560M range, but the company remains unprofitable with an operating loss of $7.0M, and the quality of the beat is low due to its reliance on non-recurring items.